Donidalorsen Treatment in Children With Hereditary Angioedema

← catalyst calendar

NCT07298447 · readout ≤ 1,046 d

Sponsored by Ionis Pharmaceuticals, Inc. (industry) · IONS — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

20estimated

Sites

Countries

Italy, Poland, Spain +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-21

actual

When the study began enrolling

Primary completion

Jun 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jun 2029

estimated

The whole study's end, after follow-up

First posted

2025-12-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-05

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Hereditary Angioedema (HAE)

Intervention

Drug: Donidalorsen — also filed as ISIS 721744, IONIS-PKK-LRx

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Treatment Emergent Adverse Events (TEAEs)

measured over the period of approximately 17 months

Maximum Plasma Concentration (Cmax) of Donidalorsen

measured over the period of approximately 17 months

Maximum Time to Reach Cmax (Tmax) of Donidalorsen

measured over the period of approximately 17 months

Trough Plasma Concentration (Ctrough) of Donidalorsen

measured over the period of approximately 17 months

Permalink · IONS's whole pipeline · Catalyst calendar · Every registered study · What changed